Spahr in just a moment, but we want to get straight to the latest on the president s condition to do that lets go live to our washington dc correspondent Trevor Shirley that Walter Reed Hospital good morning trevor. And good morning. It was yesterday that the president s doctors gave an update on his health they said that he is progressing and responding to treatment but later in the day white house chief of staff mark meadows said that on friday, the president s condition was actually much worse than most americans knew. I came here wasnt feeling so well i feel much better now were working hard to get me all the way back i have to be back from Walter Reed Medical Center President Trump released that message to the American People and said he was eager to get back to the white house and the campaign you dont over the next period of a few days, i guess thats the real test so well be seeing what happens over those next cup next couple of days, the president s team of doctors shared a ros
HOUSTON, TX / ACCESSWIRE / June 14, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered i.
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) and RenovoRx (NASDAQ:RNXT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability. Earnings & Valuation This table compares Verrica Pharmaceuticals […]
Avidity Partners Management LP lifted its position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) by 12.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,500,328 shares of the company’s stock after buying an additional 718,478 shares during the quarter. Fusion Pharmaceuticals […]
Avoro Capital Advisors LLC grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 15.6% during the 4th quarter, HoldingsChannel reports. The firm owned 5,666,666 shares of the biopharmaceutical company’s stock after acquiring an additional 766,666 shares during the quarter. Xenon Pharmaceuticals comprises about 3.6% of Avoro Capital Advisors LLC’s investment portfolio, making […]